secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2024-11-29T23:59:59+00:00
Accession:  0001493152-24-048090
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716
--------------------------------------------------------------------

- Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.
- Net loss of $867,252; basic & diluted EPS of ($0.21) on 4.1M weighted avg shares.
- Cash and cash equivalents at Sept 30, 2024: just $716; total assets $177,611.
- Total liabilities $5.37M vs. stockholders deficit ($5.19M); accumulated deficit $20.6M.
- Company remains development-stage; no FDA approvals for any product candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/0001493152-24-048090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000149315224048090/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer